20240128-德邦证券-医药行业周报_国企改革进一步深化_重视中药+国改_18页_2mb

Summary of the provided pharmaceutical industry report:

The report covers the week of January 22-26, 2024, analyzing the pharmaceutical and biotechnology sector. Key points include:

• Market performance: The Shenyang Pharmaceutical Index declined by 27%, underperforming the CSI 300 Index by 47 percentage points, with the sector ranking 28th in the combined index. Year-to-date, the index dropped 16%, worse than the CSI 300's -92%. High-growth stocks, particularly in CXO (Contract Research Organizations) like pharmaceutical giant Huaren Pharmaceutical, faced significant sell-offs due to external factors, such as US-China tensions. Top performers included companies like Huaren Pharmaceutical, which saw price adjustments.

• Fund holdings analysis: Public fund holdings in pharmaceuticals rose slightly, with firms like Mirapharma and Hualan Biological Products leading the portfolio. Q4 showed an increase in funds focusing on large-cap stocks, driven by regulatory themes and innovation. Analysts highlight that while fund allocation to pharma increased (e.g., from 13.6% to higher), there's still a bias towards stability amid volatility.

• National orthographic reforms: A major theme is the proposed inclusion of market value management in central enterprise performance metrics by the State-owned Assets Supervision and Administration Commission (SASAC). This could boost国企 (state-owned) valuations, especially in sectors like traditional Chinese medicine (TCM), blood products, and pharmaceutical retail. The reforms aim for efficiency gains, potentially rewarding value creation through increased share buybacks, dividends, and market stability. This shift is expected to support companies like Huaren Pharmaceutical.

• Investment strategy: Short-term, focus on TCM due to its policy-friendly nature, low external influence, and国企 support. Key companies recommended include Hualan Pharmaceutical, Yangguang Pharmaceutical, and others in TCM. Medium to long-term outlook emphasizes innovation, international expansion, and TCM, with specific stock picks like Mirapharma, Huaren Pharmaceutical, and bio-pharma firms. Riskier bets include undervalued core assets and cyclic sectors.

• Risks identified: Potential demand shortfalls in the sector due to external dependencies or policy changes, underperformance of listed firms based on economic conditions or management, and increased competition from domestic players, especially in areas like biologics or generics.

The report concludes with a positive outlook for the sector in line with China's aging population and innovation drive, recommending strategic allocations while cautious of regulatory and market risks.